Oncology / Haematology

Adding mitomycin to BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: a randomised phase 3 trial

Trial Name: BCG+MMC  PI: Dr Emma Beardsley

Who can take part:

  • Patients with confirmed high grade pTa or stage pT1 (any grade) non-muscle invasive bladder cancer on initial or re-resection histology

Exclusion criteria:

  • Contraindications or hypersensitivity to investigational products, BCG and MM
  • Prior treatment with any other intravesical agent including BCG or MM (excludes single doses given post TURBT)
  • Current or past transitional cell carcinoma (TCC) of the upper urinary tract

For further information please contact Theresa – 03 9784 8562

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4